Why us?  Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

 Author  Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making. Authored and medically reviewed by Dr Farzana Khan.

MD MRCGP DFFP
Was this answer helpful?
Rate Dr Farzana's explanation
faq Vaginal Laxity (postnatalmenopause support)

What does treatment feel like and what is the downtime?

Energy-based vaginal treatments (laser or radiofrequency) are usually brief, clinic-based sessions. Most people describe a warm, prickly or pressure sensation; discomfort is typically mild and short-lived. Expect a few days of watery discharge, light spotting or tenderness, and pausing high-friction activities and penetrative sex until comfortable (often 2–7 days). Foundations come first; devices are adjuncts. Educational only. Results vary. Not a cure.

Clinical Context

Good candidates. Postnatal or peri-/post-menopausal women with mild, entry-focused symptoms (air-trapping, early-penetration discomfort, reduced “support feel”) that persist after an excellent block of pelvic floor rehab and optimised GSM care. Symptoms should be stable with no active infection or unexplained bleeding.

Who should delay or avoid. Pregnancy, active BV/thrush/UTI, fever, malodorous discharge, new post-menopausal bleeding, immediately after pelvic/perineal surgery without clearance, poorly controlled pelvic pain, suspected prolapse beyond the introitus, or certain implants where electromagnetic interactions are a concern—discuss specifics with your clinician.

Aftercare essentials. Breathable cotton underwear; lukewarm water or bland emollient as a soap substitute; scheduled moisturiser and generous, compatible lubricant for any higher-friction activity (water-based for versatility/condoms; silicone-based for longest glide; avoid oil with latex); resume sex and sport when tenderness settles (often within a week). Track outcomes that matter to you and review at 6–12 weeks.

Evidence-Based Approaches

NICE guidance (menopause context): Recommends first-line use of vaginal moisturisers/lubricants and considering low-dose local vaginal oestrogen when symptoms affect quality of life; device therapies are not routine first-line (NICE NG23).

NICE urinary incontinence/prolapse: Emphasises supervised pelvic floor muscle training as first-line and clear criteria for escalation—principles that underpin selection before considering devices (NICE NG123).

NHS patient information: Practical, plain-English advice on pelvic floor training and when to seek help for related symptoms (NHS pelvic floor exercises).

Cochrane reviews (energy-based therapies): Methods-rigorous overviews of vaginal laser/RF report small studies, varied protocols and short follow-up, supporting cautious, adjunctive positioning and careful consent (Cochrane Library – vaginal laser/radiofrequency).

Regulatory perspective (UK): Information on medical device regulation, marking (UKCA/CE) and vigilance supports safe selection and reporting of suspected adverse events (MHRA – medical devices).

Pathophysiology & GSM (peer-reviewed): Public abstracts summarise how oestrogen decline affects mucosa, pH and microbiota, explaining why GSM care remains central alongside any procedural step (PubMed overview).